Matches in SemOpenAlex for { <https://semopenalex.org/work/W59138069> ?p ?o ?g. }
Showing items 1 to 84 of
84
with 100 items per page.
- W59138069 abstract "571 Objectives: Response to PRRT was monitored using Ga-68-DOTA-NOC-somatostatin-receptor-PET/CT (SSR-PET, “molecular response”) in comparison to F-18-FDG-PET/CT (FDG, “metabolic response”) and contrast-enhanced CT alone (ceCT, “morphologic response”). Methods: In 25 patients (57.5±13.4 years) with metastasized NETs, 138 discrete lesions were analyzed by SSR-PET, FDG and ceCT alone, pre and post treatment (up to 3 cycles). RECIST criteria for ceCT, and modified EORTC criteria for SSR-PET and FDG were applied to assess the response. Maximum standardized uptake values (SUVmax) were measured, and a Response Index (RI= 100 x [(post-PRRT SUVmax)-(pre-PRRT SUVmax)] / pre-PRRT SUVmax) was calculated for each lesion. ROC was calculated for SSR-SUVmax of metastatic liver lesions. SD, PR, and PD were determined for response assessment and correlated with clinical/biochemical improvement. Results: No significant correlation was found amongst the three different modalities. Molecular response were seen in 13 patients (PR 60%, SD 24%, PD 16%), and metabolic responses in 6 patients (PR 36%, SD 55%, PD 9%), respectively, whereas ceCT alone showed either SD (64%) or PD or PR (16% each). The cut-off value of SSR-SUVmax >2.5 predicted molecular response of metastatic liver lesions to PRRT with a sensitivity of 88.9% and a specificity of 71.4%. Conclusions: Ga-68-DOTA-NOC-SMS-receptor-PET/CT is superior to ceCT alone for the early assessment of response to PRRT in metastatic NET (molecular response precedes morphology)." @default.
- W59138069 created "2016-06-24" @default.
- W59138069 creator A5051446048 @default.
- W59138069 creator A5059645727 @default.
- W59138069 creator A5062424480 @default.
- W59138069 creator A5073284312 @default.
- W59138069 date "2008-05-01" @default.
- W59138069 modified "2023-09-28" @default.
- W59138069 title "Monitoring response to peptide receptor radionuclide therapy (PRRT) in patients with metastasized neuroendocrine tumors (NET): Quantitative intra-individual comparison between Ga-68-DOTA-NOC, F-18-FDG-PET/CT, and CT alone" @default.
- W59138069 hasPublicationYear "2008" @default.
- W59138069 type Work @default.
- W59138069 sameAs 59138069 @default.
- W59138069 citedByCount "0" @default.
- W59138069 crossrefType "journal-article" @default.
- W59138069 hasAuthorship W59138069A5051446048 @default.
- W59138069 hasAuthorship W59138069A5059645727 @default.
- W59138069 hasAuthorship W59138069A5062424480 @default.
- W59138069 hasAuthorship W59138069A5073284312 @default.
- W59138069 hasConcept C126322002 @default.
- W59138069 hasConcept C127077266 @default.
- W59138069 hasConcept C150903083 @default.
- W59138069 hasConcept C170493617 @default.
- W59138069 hasConcept C199374082 @default.
- W59138069 hasConcept C207001950 @default.
- W59138069 hasConcept C2775842073 @default.
- W59138069 hasConcept C2776297358 @default.
- W59138069 hasConcept C2779066768 @default.
- W59138069 hasConcept C2779931791 @default.
- W59138069 hasConcept C2779984678 @default.
- W59138069 hasConcept C2989005 @default.
- W59138069 hasConcept C2993559085 @default.
- W59138069 hasConcept C3017732841 @default.
- W59138069 hasConcept C31760486 @default.
- W59138069 hasConcept C535046627 @default.
- W59138069 hasConcept C71924100 @default.
- W59138069 hasConcept C80115893 @default.
- W59138069 hasConcept C86803240 @default.
- W59138069 hasConceptScore W59138069C126322002 @default.
- W59138069 hasConceptScore W59138069C127077266 @default.
- W59138069 hasConceptScore W59138069C150903083 @default.
- W59138069 hasConceptScore W59138069C170493617 @default.
- W59138069 hasConceptScore W59138069C199374082 @default.
- W59138069 hasConceptScore W59138069C207001950 @default.
- W59138069 hasConceptScore W59138069C2775842073 @default.
- W59138069 hasConceptScore W59138069C2776297358 @default.
- W59138069 hasConceptScore W59138069C2779066768 @default.
- W59138069 hasConceptScore W59138069C2779931791 @default.
- W59138069 hasConceptScore W59138069C2779984678 @default.
- W59138069 hasConceptScore W59138069C2989005 @default.
- W59138069 hasConceptScore W59138069C2993559085 @default.
- W59138069 hasConceptScore W59138069C3017732841 @default.
- W59138069 hasConceptScore W59138069C31760486 @default.
- W59138069 hasConceptScore W59138069C535046627 @default.
- W59138069 hasConceptScore W59138069C71924100 @default.
- W59138069 hasConceptScore W59138069C80115893 @default.
- W59138069 hasConceptScore W59138069C86803240 @default.
- W59138069 hasLocation W591380691 @default.
- W59138069 hasOpenAccess W59138069 @default.
- W59138069 hasPrimaryLocation W591380691 @default.
- W59138069 hasRelatedWork W129878204 @default.
- W59138069 hasRelatedWork W1702325671 @default.
- W59138069 hasRelatedWork W2067051163 @default.
- W59138069 hasRelatedWork W2228907525 @default.
- W59138069 hasRelatedWork W2280498124 @default.
- W59138069 hasRelatedWork W2309529296 @default.
- W59138069 hasRelatedWork W2312724636 @default.
- W59138069 hasRelatedWork W2516363637 @default.
- W59138069 hasRelatedWork W2557301392 @default.
- W59138069 hasRelatedWork W2566209313 @default.
- W59138069 hasRelatedWork W2796043744 @default.
- W59138069 hasRelatedWork W2940207815 @default.
- W59138069 hasRelatedWork W2963220737 @default.
- W59138069 hasRelatedWork W2980335522 @default.
- W59138069 hasRelatedWork W3135202571 @default.
- W59138069 hasRelatedWork W3136108579 @default.
- W59138069 hasRelatedWork W3158325261 @default.
- W59138069 hasRelatedWork W3164204777 @default.
- W59138069 hasRelatedWork W55210118 @default.
- W59138069 hasRelatedWork W2334404211 @default.
- W59138069 hasVolume "49" @default.
- W59138069 isParatext "false" @default.
- W59138069 isRetracted "false" @default.
- W59138069 magId "59138069" @default.
- W59138069 workType "article" @default.